These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 21649688

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multidisciplinary management of refractory insulinomas.
    Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ.
    Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
    [Abstract] [Full Text] [Related]

  • 5. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH.
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.
    Bernard V, Lombard-Bohas C, Taquet MC, Caroli-Bosc FX, Ruszniewski P, Niccoli P, Guimbaud R, Chougnet CN, Goichot B, Rohmer V, Borson-Chazot F, Baudin E, French Group of Endocrine Tumors.
    Eur J Endocrinol; 2013 May; 168(5):665-74. PubMed ID: 23392213
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of metastatic malignant insulinomas. 2 cases].
    Mounedji-Boudiaf L, Rougier P, Culine S, de Baere T, Lasser P, Escudier B, Ducreux M, Kaloustian E, Droz JP, Roche A.
    Presse Med; 1995 May 27; 24(19):894-6. PubMed ID: 7638129
    [Abstract] [Full Text] [Related]

  • 10. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Ito T, Igarashi H, Jensen RT, Takayanagi R.
    Fukuoka Igaku Zasshi; 2012 Jul 27; 103(7):131-7. PubMed ID: 22978065
    [No Abstract] [Full Text] [Related]

  • 11. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN, Syrigos KN, Saif MW.
    JOP; 2014 Jul 28; 15(4):351-3. PubMed ID: 25076341
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G, Katsios C, Roukos DH.
    Expert Rev Gastroenterol Hepatol; 2011 Oct 28; 5(5):563-6. PubMed ID: 21910571
    [No Abstract] [Full Text] [Related]

  • 14. Perspectives in the development of novel treatment approaches.
    Yao JC, Catena L, Colao A, Paganelli G.
    Tumori; 2010 Oct 28; 96(5):858-73. PubMed ID: 21302643
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment: symptomatic treatment of hypoglycaemia.
    Tabarin A, Goichot B, French Endocrine Society.
    Ann Endocrinol (Paris); 2013 Jul 28; 74(3):196-9. PubMed ID: 23791453
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
    Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG.
    Horm Res; 2006 Jul 28; 65(3):120-5. PubMed ID: 16479142
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.